Clin2
NCT07264413Possibly a fitNot yet recruiting

Embolization to reduce bleeding from hemorrhoids

HemorrhoidHemorrhoid Bleeding

Part of Digestive system, Heart & circulation clinical trials.

This study tests a procedure called hemorrhoidal artery embolization (HAE) that blocks blood flow to bleeding hemorrhoids to reduce or stop the bleeding. It's for people with moderate to severe bleeding from internal hemorrhoids who have not recently had other treatments.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
250 people
Ages
18 years and older
Study type
Observational

Who can take part

  • You have bleeding hemorrhoids that are grade II or III, and your bleeding is significant enough (score of 3 or higher on a standard bleeding scale).
  • You are scheduled to receive a treatment called hemorrhoidal artery embolization (HAE) using special coils to block blood flow.
  • You have not had hemorrhoid surgery before, and you have not had other hemorrhoid treatments (like rubber band ligation) within the past year.
  • You do not have certain conditions like an infection near the anus, inflammatory bowel disease, an abnormal tunnel, colorectal cancer, or weakened sphincter control.
  • You do not have a weakened immune system, severe blocked arteries, unstable angina, or a life expectancy of less than one year.
  • You are not currently taking a medication called nicorandil.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07635784Recruiting
Hemorrhoid Treatment Registry: Tracking Embolization Safety

This registry collects information about a minimally invasive procedure called hemorrhoidal artery embolization (HAE), which blocks blood vessels feeding internal hemorrhoids. It's for adults with persistent bleeding hemorrhoids that haven't improved with standard treatments like creams or medications.

Libertyville, Illinois
NCT06748014Enrolling by invitation· Early Phase 1
Study of aescin plus MPFF for bleeding hemorrhoids

This study tests whether a combination of two medicines (aescin and MPFF) can stop bleeding from mild internal hemorrhoids (grade 1 or 2) and prevent it from coming back. If you have had active bleeding within the past 7 days, this trial may help you find an effective non-surgical treatment.

Chiang Mai, Maung
NCT07179601Recruiting
Embolization for hemorrhoid symptoms study

This trial tests if blocking certain blood vessels in the rectum can reduce bleeding and other symptoms from hemorrhoids. If you have bothersome internal hemorrhoids that haven't been helped by other treatments or if surgery is not an option for you, this study may be a fit.

Los Angeles, California
NCT05697562Recruiting
Embolization treatment for hemorrhoid bleeding

This trial studies a procedure that blocks blood flow to bleeding hemorrhoids (called superior rectal arterial embolization). It may help people with hemorrhoid bleeding who are being considered for treatment, especially when bleeding is significant.

Jette
NCT07844629Not yet recruiting· Phase 2
Embolization versus surgery for bleeding hemorrhoids

This study compares two ways to stop bleeding from internal hemorrhoids: a procedure that blocks the blood supply to the hemorrhoid (embolization) versus traditional surgery. The goal is to see which treatment is safer and works better to control bleeding and improve quality of life.

Aurora, Colorado
NCT06106269Recruiting
Outcomes of rectal artery embolization for bleeding hemorrhoids

This study looks at how well rectal artery embolization (a procedure that uses tiny particles to block blood flow to hemorrhoids) works for treating bleeding internal hemorrhoids. It aims to understand if this treatment improves quality of life and reduces symptoms.

Rochester, Minnesota

Hear when a new Hemorrhoid Bleeding trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.